Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.

Ida, Motoko; Nishida, Akito; Akiho, Hiraku; Nakashima, Yoshihiro; Matsueda, Kei; Fukudo, Shin

Ida, Motoko; Nishida, Akito; Akiho, Hiraku; Nakashima, Yoshihiro; Matsueda, Kei; Fukudo, Shin.

Afiliação

Ida M; Japan-Asia Planning & Administration, Medical & Development, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411 Japan.
Nishida A; Development Project Management, Astellas Pharma Inc., Tokyo, Japan.
Akiho H; Japan-Asia Clinical Development 2, Development, Astellas Pharma Inc., Tokyo, Japan.
Nakashima Y; Japan-Asia Data Science, Development, Astellas Pharma Inc., Tokyo, Japan.
Matsueda K; Sakura Life Clinic, Tokyo, Japan.
Fukudo S; Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Biopsychosoc Med ; 11: 7, 2017.

Article em En | MEDLINE | ID: mdl-28293280

Palavras-chave

5-hydroxytryptamine (5-HT); Abdominal discomfort; Abdominal pain; Global improvement; Irritable bowel syndrome severity index; Stool consistency

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies Idioma: En Revista: Biopsychosoc Med Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google